Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen

Inclusion Criteria

• •Prior to study specific examinations the patient and if applicable both legal guardians has to give his/her written informed consent
• •Patients of both gender aged from 18 and 55 years
• •Patient's perception of disease activity of at least 30 mm on a 100 mm visual analogue scale (VAS)
• •FEV1 greater or equal than 80% of the expected value, and if not, improvement of FEV1 greater than 12% after bronchodilation
• •Patients have to suffer from allergic complaints (rhinitis and/or rhinoconjunctivitis with or without mild intermittent allergic asthma) caused by clinical sensitization against Olea europaea pollen. The IgE mediated sensitization has to be verified by:
• •Suggestive medical history
• •Specific IgE against Olea europaea pollen CAP RAST ≥0.7Ku/l
• •Positive skin prick test (SPT) to grass Olea pollen resulting in a wheal diameter of at least 3 mm.